**REVIEW ARTICLE**

# Nanocapsules: A Promising Drug Delivery System for Poorly Bioavailable Drugs

M.C Sreekanth[*1,2], V Muruganantham[1*], B.S Venkateswarlu[1], R Margaret Chandira[1], S. Shanmuganathan[3]

[1]*Department of Pharmaceutics, Vinayaka Mission's College of Pharmacy, Vinayaka Mission's Research Foundation-Deemed to be university (VMRFDU), Salem, 683008, Tamil Nadu, India.*
[2]*Department of Pharmaceutics, St John's College of Pharmaceutical Sciences and Research, Kattappana, Kerala 685515, India.*
[3]*School of Pharmacy, Sri Balaji Vidyapeeth, SBV campus, Pillaiyarkuppam, Pondicherry, 607402, India.*

***Received: 24th Oct, 2024; Revised: 26th Dec, 2024; Accepted: 17th Jan, 2025; Available Online: 25th Mar, 2025***

**ABSTRACT**
Nanocapsules propose a hopeful solution for recuperating the delivery of inadequately bio available medications, providing benefits such as increased solubility, enhanced bioavailability, and targeted delivery. They can summarize a wide range of therapeutic agents, improving efficacy and reducing side effects. Continued advancements in nanotechnology and materials science are enhancing nanocapsule design, opening doors for new treatments. Future research should prioritize optimizing these systems for clinical use and addressing stability and regulatory challenges. The victorious assimilation of nanocapsules into majority medicine could revolutionize treatment options for complex drug formulations.
**Keywords**: Nanocapsules, Drug Delivery system, poorly soluble drugs, bioavailability
**How to cite this article:** M.C Sreekanth, V Muruganantham, B.S Venkateswarlu, R Margaret Chandira, S. Shanmuganathan. Nanocapsules: A Promising Drug Delivery System For Poorly Bioavailable Drugs. International Journal of Drug Delivery Technology. 2025;15(1):316-28. doi: 10.25258/ijddt.15.1.44
**Source of support:** Nil
**Conflict of interest:** None

## INTRODUCTION

By distributing the medication to the location of action, novel medication delivery systems can boost the bioavailability of the medication. This reduces the drug's impact on important tissues and reduces unwanted side effects, which leads to a raise in the accretion of healing compounds at the objective place and, ultimately, a diminish in the quantity of medication needed at a predetermined rate [1,2]. Recent advancements in nanotechnology have verified the enormous potential of nanoparticles—structures smaller than 100 nm—as medication carriers. Because of their tiny sizes, these nanostructures have special physicochemical and biological qualities (such as an increased reactive area and the capacity to pass through tissue and cell barriers), which makes them a useful substance for biomedical purposes. Because nanoparticles contain a higher exterior region to dimensions proportion than other particles, more exterior region is bare, ensuing in earlier conclusion of the particles in clarification, lower dosage requirements, less toxicity, and higher bioavailability. Most therapeutic molecules are dispersed all through the body by systemic blood flow in predictable medication delivery methods, such as oral or intravascular delivery, meaning that most particles do not reach their intended goals and instead stay in the corpse and cause consequences. Due to their short plasma half-life, low serum stability, probable immunogenicity, and insolubility in water, the medication and therapeutic molecules are quickly unfurnished by the Mononuclear phagocytic system (MPS), it reduces their effectiveness. The term "bioavailability" explains how rapidly and to what degree the lively component (drug or metabolite) goes into the bloodstream and reaches the position of action. The Novel Drug Delivery System such bilosomes, noisome, liposomes, phytosomes, etc., which go by the presystemic metabolism, minimizing harmful results because of the accumulating of pharmaceuticals to the no targeted places and recuperating tissue macrophage division in patients of all ages [2-3]. This acts to boost permeability, stability, solubility, along with sustained delivery while protecting against physical and chemical degradation[4]. The Noyes-Whitney equation can be used to establish a drug's dissolving rate, which also straightly correlates to surface area as particles get smaller. Consequently, medications that are inadequately soluble in water have augmented saturation solubility and dissolving rate. Oral lipophilic medications become the rate-limiting stage in the absorption and dissolution processes. The Biopharmaceutics Classification System (BCS) [5] provides a clear explanation of intestinal permeability and medication absorption solubility. This review article focuses on various innovative drug delivery methods that can be used to boost the bioavailability of medications that are defectively soluble.

***Author for Correspondence:** *sreekanthmc85@gmail.com*



Figure 1: Structure of Nanocapsule

**Nano based drug delivery systems**

Important advancements includes recently in the pasture of delivery structures to move active substances or else medicinal representatives copied from normal sources to their proposed place for therapy of different illnesses [7,8]. Even though many medication delivery systems include effectively used in recent times, there are still some issues to necessitate being determined, in addition to cutting-edge tools requirements to be produced in order to effectively distribute pharmaceuticals to their planned locations. Consequently, studies are currently being conducted on nano-based medication delivery systems, which will allow more advanced medication.

*Basics of a drug design approach based on nanotechnology*

Using materials at the nanoscale to prevent and treat a variety of ailments, nanomedicine is the region of medication that makes utilize of the science of nanotechnology such as nanorobots [10] and biocompatible nanoparticles [9] for a range of uses, for instance actuation in a living creature,[14] delivery,[12] diagnostics[11] and sensory.[13] Medications by means of extremely low solubility had a number of problems with biopharmaceutical delivery, such as poor bioavailability after oral ingestion, a reduced ability to disperse into the outer membrane, a greater need for intravenous administration, and unfavourable consequences that come before the standard inoculation procedure. However, by utilizing nanotechnology methods in the drug delivery system, all these limitations might be separated. Because of its immense research, drug designing at the nanoscale is by distant the most complicated technique in the meadow of nanoparticle relevances.

Possible benefits include the capacity to change features including diffusivity, immunogenicity, drug release patterns, solubility, and bioavailability. Consequently, there may be a raise in the creation of convenient delivery methods, a diminish in adverse effects, enhanced biodistribution, a reduce in toxicity, and a long-lasting drug life cycle.[6] The intended medication DS are planned for the controlled discharge of healing substances on certain site or furthermore targeted to a particular place. They form by self-assembly, in which separate arrangements or patterns appear from construction pieces on their own.[15] They also need to get precedent obstacles like the mononuclear phagocyte system's opsonisation/sequestration.[16]

Nanostructures can dispense medications in two ways: passively and through self-delivery. In the previous, the hydrophobic effect is mainly dependable for the incorporation of medicines into the centre cavity of the formation. Because the medicine is enclosed in a hydrophobic environment, its low content permits for the targeted release of the prescribed dosage when the nanostructure substances are applied to precise areas.[15] In contrast, the latter method simplifies distribution by in a straight line conjugating the drugs aimed for liberate to the haulier nanostructure substance.

During this method, the release timing is significant because if the medicine is free from its nanocarrier system at the wrong period, its bioactivity also efficiency will be reduced and it will not reach the target place as it will rapidly separate from the haulier.[15] Another main area of medication delivery that employs active and passive nanoparticles or nanoformulations is targeting of pharmaceuticals. Active targeting absorbs the coupling of molecules, including peptides and antibodies, with a medication delivery mechanism to bind them to the receptor.

When a drug carrier complex is created for passive targeting, it goes through the flow and is bound to the aim location via similarity, which is in time by factors such as pH, shape, site, molecular and temperature. The body's primary targets are lipid factors the membrane of cell, and antigens on cell surfaces or receptors on cell membranes proteins.[17]At present, on the way to the cancer disease and it's healing; most nanotechnology-mediated medication delivery systems are concentrated.

*Typical Ingredients for Polymeric Nanocapsule Preparation*

*Polymeric Shell*

With the intention of load, preserve, and release bioactive chemicals inside polymeric nanocapsules, shell materials are important. The stability, biodistribution of nanocapsules as medication delivery systems, encapsulation effectiveness and release profile are all considerably impacted by the properties of polymers.

Biocompatible polymeric equipment have been given cautious deliberation as appropriate possibilities for the manufacture of nanocapsules. Predominantly, these polymers should be recyclable in order to liberate the consignment as well as eliminate the nanoparticles. However, biocompatible polymers so far non-biodegradable like polyethylene glycol (PEG) and polyvinyl alcohol (PVA) enclose broadly engaged towards aid in the creation of nanoparticles. They have the hydrophilicity to aid in medication discharge through strength.

Besides, even if they weren't broken down into slighter molecules, they may ultimately be removed from blood by means of the reticuloendothelial system.[18,19] For the formulation of nanocapsules, a range of polymers have

Table 1: Overview of Nanocapsules

| Type of Nanocapsule | Core Material | Shell Material | Preparation Method | Advantages | Application |
|---|---|---|---|---|---|
| Polymeric nanocapsules | Drugs, proteins, nucleic acids | Biodegradable polymers (e.g., PLA, PLGA, PCL) | Emulsion-solvent evaporation, nanoprecipitation | Controlled drug release, biocompatibility | Drug delivery, cancer therapy |
| Lipid nanocapsules | Hydrophobic/hydrophilic drugs | Phospholipids, surfactants | Phase inversion temperature, solvent diffusion | Enhanced bioavailability, low toxicity | Oral/IV drug delivery, gene therapy |
| Inorganic nanocapsules | Imaging agents, drugs | Silica, calcium phosphate | Sol-gel synthesis, layer-by-layer assembly | Imaging capability, high stability | Bioimaging, theranostics |
| Protein-based nanocapsules | Small molecule drugs | Albumin, gelatin, casein | Coacervation, desolvation | Biodegradability, low immunogenicity | Targeted delivery, enzyme encapsulation |
| Hybrid nanocapsules | Drugs, biomolecules | Polymer-lipid/silica hybrid shells | Combined methods (e.g., emulsion + sol-gel) | Tunable properties | Combination therapy, diagnostics + treatment |

been used to meet the desires of different applications. Shell depending on where they come from, they can be measured as synthetic or natural polymers. Among the most crucial classes of naturally stirring polymeric resources, polysaccharides has found extensive application like medication hauliers due to their mucoadhesive qualities, biocompatibility, and gelation conditions. Usually speaking, deprotonated amino groups, polysaccharides are rich in carboxylic acid or, which provide anionic or else cationic charges and help form the polymeric shell through electrostatically positive interfaces.[20–22] Because of its mucoadhesive qualities, gelation conditions, biocompatibility, and endogenous metabolizable degradable products, chitosan, a common natural polymer, have widely engaged as a medication carrier. [23, 24] Chitosan-covered or -formed nanocapsules can process a cationic exterior charge that gains from chitosan's abundant amino groups. Through electrostatic interactions, bacteria that process harmful surfaces can interact with nanoparticles more effectively when the surface is cationic. In comparison to those without chitosan, PLGA nanocapsules with a chitosan shell demonstrated superior connection to *M. abscessus* and *S. aureus*.[25]

It resulted in the invention of chitosan-based nanocapsules as a means of delivering medications for infectious sickness.[26] However, the significant cationic surface charge may cause quick clearance from the blood circulation, protein adsorption, and nanoparticle aggregation for different applications.[20, 21] Accordingly, chitosan and a number of anionic polymers have been combined to function as nanocapsules. Shells, such as poly (acrylic acid) (PAA),[27] anionic polysaccharides [29,30] and poly (vinyl alcohol) (PVA) [28] in order to tackle this issue.

Alginate has been exploiting as a medication carrier owing to its low immunogenicity, favorable gelation conditions, and biocompatibility [31–33] between the anionic natural polysaccharides. Apart from these extensively familiar advantages, while making possible medication discharge in alkaline pH environments, [34] alginate was a pH-responsive polymer so as to be able to successfully guard payloads in acidic pH environments. As a result, alginate-based nanocapsules have been produced as a potentially effective oral medication delivery method for the intestines, [35] Dextran sulfate is a polyanionic polymer that is both biocompatible and biodegradable, and it has used widely utilized in drug delivery applications in the pharmaceutical industry.[36] Normally, dextran sulfate and chitosan work together to create multilayer nanocapsules through electrostatic integration.[37] Without the requirement for additional covalent agents, nanocapsules based on chitosan–dextran sulfate established high strength.[38] Moreover, to influence the drug release behaviour the ratio of chitosan to dextran can be adjusted. Consequently, enhancing the gene release in cytoplasm or serum, Chitosan–dextran nanoparticles generated among larger proportion of carboxymethyl dextran might improve the nanoparticle dissociation. [39, 40] Furthermore, the above-mentioned general polysaccharides—poly heparin,[42] hyaluronan,[43] (cyclodextrin),41 and others—have been consumed to create nanocapsules that serve as drug carriers for dissimilar pharmaceutical functions. Because of their tuneable characteristics and biocompatibility, [44,45] protein-based polymers, had been treated as polymeric case for nanocapsules, is the another kind of natural macromolecules. A protein that is recyclable and soluble in water, albumin acts a very important role in the circulatory system.[46] The shell of human being serum albumin has been used to contain nanocapsules. As well as albumin corona can lessen the immunogenicity of nanoparticles, regulating the rate at which drugs penetrate the body, helping them to avoid the reticuloendothelial structure remodelling. Because albumin was biogenic, it can moreover act as intentioned drug for albondin receptors, which were over expressed on tumor blood vessel endothelial cells. This makes albumin a perfect drug targeting system.[47] In addition, protein can be anticipated to self-assemble into a concave caged nanostructure from a predetermined quantity of subunits. These virus-like synthetic nanocapsules have a extremely fine size division and can carry drugs. For example, like a drug transporter for the anti-tumor agent doxorubicin, a HspG41C mutant protein-based nanocapsule was produced. It was made through the forming itself of 24 distinct single stranded proteins. The HspG41C nanocapsule can be processed to a particle size of roughly 12 nm with a constricted dimension division and is readily manufactured using a self-assembly technique in a water environment. It efficiently administered doxorubicin to a range of cancer cell lines and demonstrated good biocompatibility.[48] Ren et al. created a different protein-based caged nanostructure as a doxorubicin drug delivery method.[49] It was produced by 60 dihydrolipolyl acyltransferase subunits (E2) self-assembling, yielding particles that were around 25 nm in size. While artificial resources can be produced with purity and reliable quality, they have advantages over natural materials. Moreover, they can be modified to have different ionic, soluble, mechanical and degradable qualities in accordance with various pharmacological applications.[50] Because of their aliphatic polyesters and related copolymers, biocompatibility and biodegradability—which are highly prevalent artificial polymers—have been extensively researched and developed as medication delivery systems. Poly (lactic acid) (PLA), Poly (lactic-co-glycolic acid) (PLGA) and Polycaprolactone (PCL) were mainly used polyesters. Contrasted with PLGA and PLA co-polymers, PCLs can present substantially more humiliation duration. PCLs are consequently better suited for long-term medication medical applications or delivery systems. In addition, some study point towards that PCLs are less expensive than PLGAs and PLAs and which is also advantageous. [78,25,51–53]Furthermore, because of their stretchy ionic properties, biocompatibility, and biodegradability, a variety of synthetic polymers with variable ratios of methacrylate and acrylate segments, known as Eudragit® polymers, have been used in medicine to cover drugs with various suggested dosage forms.[50] The formulation of nanocapsule shells has been contemplated with the utilize of Eudragit® polymers.

For the liberation of dihydromyricentin, for example, a polymeric shell has been formed using Eudragit® RS100. Eudragit® RS100 was made together of methyl methacrylate, ethyl acrylate, and methacrylic acid esters and can supply 4.5%–6.8% quaternary ammonium groups [54]

*Advantages*

DNA's negative charge can be neutralized by the ammonium groups of Eudragit® RS100, allowing the molecule to pass through the cell membrane unscathed.[55] Additionally, a hydrophilic synthetic polymer, poly (ethylene glycol) (PEG) that is biocompatible, has been broadly employed as a polymeric coating for nanocapsules. formulation for self-assembled nanocapsules employing amphiphilic PEG copolymer,[56] PEG coating following nanocapsule formation [57]or such as PLGA-PEG copolymer, are two ways to obtain PEGylation. It have been established that nanocapsules with PEG showing on the exterior can lessen immunogenicity and increase nanocapsule stability in biologic media[24,58,59]

*Solid/Liquid/ void Core*

Nanocapsules can include a liquid or solid core, or they can be hollow, which allows them to hold various medications. Lipophilic compounds can be encapsulated in nanocapsules due to their oleic core.[30] Because of its ability to melt lipophilic medicines and its safety, fatty acids (like average chain triglycerides) or vegetable oil (like soybean, palm, etc.) make up the ideal composition of the oily core for the construction of nanocapsules.[25,60,61]
In addition to acting as a drug dissolving medium, the oil is a promising contender for the oleic core of nanocapsules because it also has therapeutic properties. Copaiba oil was used as the oily core of a PCL nanocapsule to increase the solubility of imiquimod, a hydrophobic anti-cancer drug. Copaiba oil, on the other hand, has analgesic properties and anti-inflammatory and is beneficial for the treatment of neoplastic melanoma and micropapillary carcinoma.[62]
In the development of Eudragit® RL 100, Açai oil (AO) was used as the oily hub nanocapsules, which were encumbered with the anti-inflammation medication desonide. In addition to acting as an oil basis for medicine encapsulation, AO demonstrated anti-proliferative and anti-inflammatory benefits that corresponded to the remedy.[61] Essential oils with antibacterial, antioxidant, antifungal, antimutagenic, and anticarcinogenic qualities, like lemongrass and turmeric oil, have been employed as lubricate core.[63] To dole out as a stage for the constant delivery of hydrophilic complex, [64] aqueous core polymeric nanocapsules can also be produced. Doxorubicin and gemcitabine hydrochloride are two examples of hydrophilic anti-cancer medications that have been effectively summarized into polymeric nanocapsules with an aqueous core.[65, 66] Drug-loaded nanocapsules had a greater anti-cancer effect as compared to free drug. Furthermore, the hydrophilic bioactive material can be effectively encapsulated and protected by the polymeric nanocapsules with an aqueous core. For example, the low stability and membrane permeability of mono- or oligo-nucleotides in the biological milieu have restricted their therapeutic applicability.Polymeric nanocapsules' aqueous core encapsulation effectively shields the contents from deterioration in biological fluids and encourages intracellular penetration, which raises the contents' bioavailability.[67,68] Moreover, the option for delivering water-soluble proteins, like albumin, is to use polymeric nanocapsules with an aqueous core.[69] Additionally, an internal hollow structure is another characteristic of nanocapsules.[70,71] Generally, a solid sphere is prepared beforehand and sacrificed once the polymeric shell forms in order to create nanocapsules with a hollow core. In particular, a robust spherical framework can be supplied by using a hard globe as a sacrificial pattern for the assembly of nanocapsules made up of many polymer shells.

The solid sphere pattern must be removed towards create a void core, to control the in vivo medicine release and enhance the nanocapsules' biocompatibility. In command to avoid break to shells. The materials measured as the outline hub should be easily separated by gentle circumstances. After the polysaccharide shell forms, metallic elements like iron oxide [72] and gold [27,41] spheres can be removed using a solution of hydrochloric acid or potassium cyanide. Beyond its use as an oil core for medicine encapsulation, AO additionally displayed anti-inflammatory and anti-proliferative effects that were connected to the therapy,[73] calcium carbonate. Furthermore, another inorganic substance that is often employed as an outline core and may be removed by completely dissolving it in hydrofluoric acid is silica.[74]Furthermore, trichloromethane could be eliminated after treating polystyrene and using nanoemulsion to create nanospheres supplying a void.[75] Lastly, the interior nucleus of nanocapsules can also be combined into a hard circumstances polymeric medium,[76] in order towards enable loading of various payloads. For instance, pectin gel-cored nanocapsules had been created as an eye medication delivery device for the treatment of glaucoma.[77] With the help of pectin gel's porous structure and hydrophilic quality, the drug-loading yield of the nanocapsules was effective, and patient compliance was high for ocular administration. However, research on solid core nanocapsules is still in their childhood when compared to those with fatty or empty cores.

*Composition of nanocapsules*

Nanocapsules are minuscule colloidal medication delivery systems made up of an aqueous or organic phase covered in a thin polymer membrane.[79] Polymers, either synthetic or natural, may be used to make the membrane. Inside the membrane module, surfactants and water were present in the aqueous part, which eliminates the nano capsules that are formed at the pore outputs, while the polymer, oil, solvent, and drug are present in the organic segment. Two technologies are used to create these nanocapsules: “The monomer's cross-facial polymerization and polymer's interfacial deposition." The negatively or else positively charged polymer will be introduced during the capsule preparation process. To the preceding layer [81] each succeeding layer has been reverse charged. They create the poly electrolyte difficult layers' shells. It can create 4–20 layers of walls that are 8–50 nm thick for the capsule.[82]

## METHODS OF PREPARATION OF NANOCAPSULES

The preparations of different types of nanocapsules are:

- Emulsion polymerisation
- Polymerisation method
- Encapsulation of nanocapsules
- Interfacial polymerisation

**Polymerisation method**

The medication was then added by moreover dissolving in the polymerization standard otherwise by the nanoparticles' adsorptions behind the monomers were polymerized in an aqueous result to make nanoparticles.[80] The nanoparticle suspension was purified using the ultracentrifugation method, which also take away the different surfactants and stabilizers used in the polymerization progression. After that, the nanoparticles were incomplete again in a media devoid of isotonic surfactants. Making polybutylcyanoacrylate or polyalkylcyanoacrylate nanoparticles has been anticipated as a potential application. The utilization attention levels of surfactants and chemical and physical stabilizers conclude the creation of nanocapsules and the size of their particles. Using the phase-inversion procedure, the nanoparticles are prepared, in addition to the result indicates a mean diameter varies between 20–100 nm.[83]

*Emulsion polymerisation*

An example of preparing a pre-emulsion for one of the nanocapsules was provided. The pre-emulsion was manufactured by combining two portions; Part 1 comprised 40 g of Desmodur BL3175A, 40g styrene, 2'-azobisisobutyronitrile, 0.8 g Divinylbenzene0.82 g of 2, and 220 g of water, 1.70g of SDS (Sodium dodecyl sulfate), and 1.62g of Igepal CO-887 were found in part 2[9]. For ten minutes, Parts one and two be magnetically combined in different containers. Part two was added to part one, and the mixture was restless for 30 minutes at 1,800 rpm under mechanical agitation. Prior to sonication, the resultant pre-emulsion was chilled to less than 5°C using a Misonix Sonicator 3000.

A 3 neck round-bottom flask has been moved through a nitrogen intake, reflux condenser, and mechanical stirrer, the pre-emulsion was allowed to degas for thirty minutes. The temperature was elevated to 70°C to finish the polymerization process, and held there for eight hours.[84]

*Interfacial polymerisation method*

The bulk polymerization of condensation polymers is replaced by interfacial polymerization, which needs high temperatures. It consists of 2 immiscible solvents where the rate at which the monomers in one solvent react with those in the other may be affected by the time scale. Because it is more likely than the opposing monomer to stumble into a growing chain, monomers with higher molecular weights are produced.[85] A W/O emulsion can be used to produce the nanocapsules within the aqueous core containing isobutylcyanoacrylate oligonucleotides. For the manufacture of nanocapsules, both the organic and the aqueous phase are utilized. Solvent phase made up of oils, polymers, solvents, and drug molecules. Alternatively, the non-solvent phase can be made up of a non-solvent or a combination of non-solvents for the polymers, as well as 1 or more organic or synthetic surfactants. A commonly utilized biodegradable polymer in the solvent displacement method is Poly-e-caprolctone (PCL).[86]

*Encapsulation of nanocapsules*

Utilizing recent developments in encapsulating technology, micro/nanocapsules with specific application qualities have been developed for use in biology, medicine, and food.[87] The mainstream of encapsulation techniques use isocyanates in bulk or solvent to create a shell, or they apply pressure on copying paper that is sensitive. When drugs are enclosed in nanocapsules—such as Aerosil 200 and Xerogels—the release of the drug is

postponed. One significant drawback of the Aerosil200 is that the nanocapsules burst. Various techniques have been planned to decrease the rupture release of medicines from xerogel mesopores.[88]
The features that nanocapsules show vary depending on how they were made, as shown in the table below. The drug attention, release time of the active ingredient, and size of nanocapsules are all different.

## CHARACTERIZATION OF NANOCAPSULES

*Particle size*
The bioavailability, toxicity, distribution and targeting ability of nanoparticulate systems in vivo are all resolute with the dispersion and size of the particles in nanocapsule structures. Moreover, it commonly affects the ability of drugs to load and release as well as the constancy of nanoparticulate systems. The basis for the effect of the duration of pharmacological action and releasing dosage was reliant on the particle size. While the big particles with their huge core surfaces slowly disperse out, the smaller particles with their increased surface area allow most therapeutic agents attached with or next to the surface particle to direct to immediate medication release.[89] The deficiency of polymers can too be impacted by element dimension.
For example, in vitro studies on the velocity of breakdown of poly (D, L-lactide-co-glycol ide) (PLGA) polymer explained an augment with increasing particle size.[90] By means of dynamic light scattering or photoncorrelation spectroscopy the particle size is determined.[91]
*Surface belongings of the nanocapsules*
Concerning the use of nanocapsules for medication targeting, the following approaches have been successful: (a) formulating the nanocapsules using biodegradable copolymers of hydrophilic segments, such as poly-ethylene oxide (PEO), poly-ethylene glycol (PEG), poly-oxamer, poly-xamine, and poly-sorbate 80 and (b) coating the nanocapsules' surface with hydrophilic polymers and/or hydrophilic surfactants;. Charge on the surface property of a nanocapsule can be successfully characterized using its zeta potential. Necessary to extend their circulation in vivo and reduce opsonization.
*Fluorescence quenching*
The most important use of extinguishing of fluorescence [94] is to verify the location of nanocapsules, which have an aqueous hub that contains oligonucleotides. [95]

## EVALUATION STUDIES

*X-Ray Diffraction (XRD) studies*
Using graphite monochromatized a Rigaku D/max-2000 diffractometer and CuKα (λ = 0.154 056 nm) with a current of 250 mA, and a voltage of 50 kV powder XRD is used to analyze the products' phases. The segment composition of the manufactured products is displayed in the XRD pattern. [96]
*Scanning Electron Microscopy (SEM)*
The self-similar features of the structure are confirmed by the structural design of the hierarchical branching aggregates, which are categorized by nanocapsules and may have tiny clusters, giant clusters, flocculent structure, and big branches steadily at different scales. [97] It distinguishes a Philips XL-30 scanning electron microscope (SEM), which at high magnification shows the distinct morphology of tiny clusters. The minute particles stuck together to form a flocculent shape make up the clusters.[98] The coral-like architecture, which has hierarchical branching features beside lengthwise axes and the axial, may be seen in a low-magnification SEM image.
*Differential Scanning Calorimetry (DSC)*
Both clogged samples (pan-capped with a little gap in the middle) and open samples (without a lid) are subjected to DSC analysis. The published observations show that the thermal behavior of both approaches is the same.[99]
*Transmission Electron Microscopy (TEM)*
When insulin-loaded nanocapsules are managed verbally to investigational rats for both in vivo and in vitro experiments, using TEM, the transport of these particles across the epithelium can be assessed. Insulin is transferred across the mucosa as a result of intestinal absorption of biodegradable nanocapsules, according to the TEM results. [100]
*High-Resolution Transmission Electron Microscopy (HRTEM)*
Using high-resolution transmission electron microscopy was investigated; the shell/core formation of the matching nanocapsules is evident in their exact morphology. [101]The TEM images obtained at low magnification are used to inspect the shape of the nanocapsules that form the collections.
*X-Ray Photoelectron Spectroscopy (XPS)*
X-ray photoelectron spectroscopy capacity are conceded out to distinguish the valency of surface aluminium atoms on the nanocapsules at a depth of 1.6 nm, using an ESCALAB-250 equipped with a monochromatic x-ray source (an aluminium Kα line at 150 W and 1486.6 eV energy). Due to the small range of photoelectrons are produced the XPS technique is very selective to the solid surface. A concentric hemispherical analyzer (CHA) is used to determine and display a spectrum with sequential stages of the photoelectron peaks, the excited energy of the photoelectrons originating from the sample. Each element has its own binding energies for the peaks. The peak regions are created to show the makeup of the outer compounds (with corresponding sensitivity factors). The emitting atom's chemical condition can vaguely change each peak's shape and binding energy. The information on chemical bonds is also provided by the XPS technique.[102]
*Superconducting Quantum Interference Device (SQUID)*
The magnetic characteristics of nanocapsules were ascertained using Quantum Design's MPMS-5s or MPMS-7s superconducting quantum intrusion devices. Due to its enormous series of potential applications, SQUIDs are the most sensitive detectors when it comes to recognizing even the smallest variations in magnetic flux.[103]
*Multi Angle Laser Light Scattering (MALLS)*
Like capsules crypts are shaped, by a big interior cavity surrounded by a tremendously thin shell (around 2 nanometers). The vault particle within a nanocapsule presents a remarkable opportunity for compound

distribution, encapsulation, and protection. [104] To find the crypt conformation, the multiangle laser light spreading [105] is employed in result in order to recognize the conditions that can endorse the interconversion of closed as well as opened conformers. These investigations permit encapsulated materials to be controlled in terms of entrapment and release. Detoxification in the environment and medicine depends on vaults that hold harmful metal binding sites.[106]

*FT-IR analysis*

The existence of feature peaks was verified by the studies of FTIR. The peaks represent the compound's feature useful groups.

## APPLICATIONS OF NANOCAPSULES

Several suitable functions are found to be for the nanocapsules. Their great reproducibility and wide range of uses stemming from their micronized size make them highly valuable in life science applications. Cosmetics, waste water treatment, agrochemicals, genetic engineering, cleaning products, and component adhesive applications are just a few of the industries in which they may find use. They also discover applicability in encapsulating the oils, adhesives, enzymes, surface polymers, organic or inorganic catalysts, inorganic nano-particles and micro-particles, biological cells, or even latex particles.

*Nanocapsules for drug delivery*

In one direction to help guide these tiny, one-thousandth of a millimeter particles from the bloodstream to an induced tumor is to wrap their surface with an antibody. Upon reaching the tumor, a sudden blast triggers the capsules to rupture and release their medicinal contents. The tiny gold particles that attach to the polymer's surface and were exact to the laser light are around 6 nm, or 6 millionth of a millimeter. This allows the drugs to point their medication load ability at the correct time. When the gold dots are showed to near-infrared light, they immediately dissolve without compromising the contents, causing the tablet to break.

*Nanocapsules for the oral administration of proteins and peptides*

Proteins and peptides and are managed orally using nanocapsules, namely recyclable poly (isobutylcyanoacrylate) nanocapsules.[107] Due to the characteristic bioavailability of these compounds the growth of appropriate carriers remains as a problematic approach. They are limited by their breakdown of digestive enzymes and the gastrointestinal barriers of the epithelium. After oral treatment, the effect was seen in diabetic rats using the encapsulation approach, which liberates the hydrolytic degradation and biologically active drug from enzymatic reaction (e.g., loaded insulin nanoparticles). [108]Bioactive peptides can be entrapped within the nanocapsules.

*Treatment of hormone dependent breast cancer*

The human estrogen receptor alpha (ERα) can be targeted by certain siRNAs enclosed in nanocapsules, according to Jack *et al*., studies [109] These nanocapsules were introduced intravenously into xenografts of MCF-7 cells treated with estradiol, and the consequence was ERα expression in tumor cells and a marked reduction in tumor growth. This recommends that ERα−siRNA delivery-based modern therapeutic approaches for hormone-dependent breast tumors may be developed.

*Nanorobotic systems guided by MRI for medical and diagnostic uses*

Embarrassingly, nanorobotic devices for human cellular and subcellular examination and repairing or reconstructive treatments have been developed under the supervision of a magnetic resonance imaging (MRI). The concept of an MRI directed nanorobotic technology,[110] which depends on an MRI scanner, produces appropriate external impulses for detonating magnetic nanocapsules at a particular location. The most recent engineering computational tools and control algorithms were recently created for achieving the profit of constant driving strength pursued by nanocapsule administration.

*Nanocapsules enabling in vivo plasmid distribution in the form of liver cells*

Both the successful transmission offered by viral vectors and the use of non-viral vectors for gene therapies have been hampered by the lack of appropriate in vivo delivery mechanisms. [111] The hyaluronan receptors (HAr) are expressed by liver sinusoidal endothelial cells (LSECs) and the aisaloglycoprotein receptors (ASGPr) are expressed by hepatocytes (heps) in large quantities, giving them ideal candidates for absorption by ligand-mediated channels.

A successful approach for encapsulating a red luminous protein (DsRed2) reporter plasmid employing whether asialoorosomucoid (ASOR) for hep or HA for sinusoidal endothelial cells of the liver (LSEC) absorption has been developed through the use of dispersion the atomization process. The receptor and drug was noncovalently bonded to the capsule covering in sub-50 nm nanocapsules produced using this technique. Heps or LSECs can receive the plasmids in vivo by ASOR- and HA-targeted nanocapsules, respectively.

*Using radioactive elements to cure cancer with nuclear nanocapsules*

Most commonly employed in the treatment of cancer, astatine is a radioactive chemical that, like uranium and radium emits high energy α particles through the process of radioactive rot, which was around four thousand times more rapid than the beta rot of the produced electrons. Because of the large particle size and poor penetrating strength the α particle was strange for targeting tumours at the solitary cellular level. [112]

*Nanocapsules for self-treatment materials*

In addition to structural composites, damage to adhesive components, microelectronics, and polymer coating materials can last longer.[113] Polymer microcapsules containing a healing component were employed to develop the novel self-restoring approach. In addition, a graphene connection to the host material fairly well, has a longer shelf life, and was sufficiently durable. With their functionalized surface surfaces and walls that can make and hold nanometer-sized things, nanocapsules are becoming admired as a way to advance the future of miniature tools that will guide to completely new curative uses within medical and technological research.

*Liposomal nanocapsules in food Science and agriculture*

Polar lipids are spread in hydrophilic solvents via liposomes, spherical bilayer vesicles. They can serve as successful drug delivery systems since they can instantly protect the most delicate and reactive components. Therapeutic materials that have been encapsulated have been stabilized by liposomal entrapment in opposition to environmental changes and a selection of chemical, including chemical modifications and enzymatic and shifts in buffering against extreme pH, ionic strength levels and temperature.

*Cosmetic formulations incorporating HKL-loaded PCL nanocapsules promote hair growth in vivo*

Comparing the hinokitiol (HKL)-containing nanocapsules to standard solutions, the emulsion diffusion method [114] explains growth stimulation and yields good capable results with histological and structural modifications of the hair follicles.

*Sun screen cosmetics comprising TiO2 nanocapsules*

TiO2 nanocapsules, created by dispersing TiO2 with surfactant, are included in a UV blocking cosmetic product to get better constancy and give UV protection without causing damage to the body. Aluminum stearate or isostearic acid-containing surface treating agents are used to pertain the oleophilic surface treatment.

*Protein-based nanocapsule molecular design for stimulus-responsive properties*

Commencing the hyperthermophilic archaeon a homogenous complex is formed by the small heat shock protein (sHSP) [115] With a molecular mass of 400 kDA and 24 subunits, it has tremendously admirable thermal stability. Employing multiple mutations (Mutant 01–10) to produce a breakage location for a particular protease (an enzyme), Factor Xa, has been tested to have released from the exterior face of the nanocapsule through hereditary engineering in order to functionalize the nano-capsule to manage the structural reaction of exterior stimuli like protease indication and temperature. Escherichia coli expressed the resultant mutations at high quantities. A globular assembly resembling that of the wild type protein was produced by Mutant 06, one of the mutants with the most endorsed cleavage at the triangle pore site on the capsule surface. The abovementioned study's findings established that Mut6 functions as a stimulus-responsive nanocapsule. A unique made of protein nanocapsule may find use as a versatile brilliant structure.

*Nanocapsules against melanomas*

Enormously aggressive tumors having a poor prognosis, mainly if they have spread, are called melanomas (cancer). The standard FDA-approved treatment, the best response rate with dacarbazine, is only 16%, despite considerable attempts to discover adjuvant medicines.[116]

The subsequent strategies ought to be used to focus on particular cancer cells: i) Passive increased penetrability preservation phenomena because of the stealth, dimension qualities of the nanocapsules and composition; ii) Linking with several antibodies to achieve active targeting.

A choice of nanocapsule varieties has been tested for their physico-chemical characteristics, blood half-life, tumor model accretion, and potential therapeutic advantages. The polylactic-co-glycolic nanocapsules containing magnetic nanoparticles and the anti-cancer drug Selol, which is based on selenium, offer a novel and effective magnetic medicine release system that may be utilized to treat cancer through magnetohyperthermia and active drug delivery.[117]

*Drug delivery via self-assembled DNA nanocapsules*

DNA is currently being used as a basic material by nanotechnology researchers.[118] Nanofabrication was used to construct a tetrahedron and a cube octahedron by the development of molecular self-assembly in basic DNA. By encasing themselves in DNA polyhedra, these molecules create proteins that can adhere to these structures on the outside. We then looked at how these therapeutic molecules got to different tissues or cells.

*Futuristic nanocapsule dressings to combat infestations*

If the remedial process was slowed or, the skin becomes impacted, the usual dressings must be removed. On the other hand, when an injury turns into contaminated, nanocapsular dressings instantaneously discharge antibiotics. They don't need to be taken out, which increases the probability that an injury will cure without leaving scars. Additionally treating other wounds like ulcers, military personnel habitually employ nanocapsular bandages when they are in struggle. Aiming remedial before the infection worsens, these therapeutic dressings deliver antibiotics via nano-capsules stimulated by the presence of causative bacterial organism or transmittable pathogen. The antibiotic capsules that provide as bandages are breaked by the bacterial toxins. By producing medicines on demand, this lowers the possibility that bacteria resistant to antibiotics, such Methicillin-resistant *S aureus* (MRSA), may evolve.

## CONCLUSION

In conclusion, nanocapsules characterize a highly promising drug delivery system for poorly bioavailable drugs, offering major advantages such as improved solubility, improved bioavailability, and targeted delivery. Their skill to summarize a diverse range of healing agents permits for greater efficacy and reduced side effects. Ongoing materials science and advancements in nanotechnology persist to refine the plan and functionality of nanocapsules, paving the way for new treatment options in different therapeutic areas. possible studies should focus on overcoming possible issues, including as stability and regulatory barriers, and improving these platforms for use in treatment. In the end, the integration of nanocapsule technology into majority medicine could transform the treatment landscape for demanding drug formulations.

## REFERENCES

1. Saharan VA, Kukkar V, Kataria M, Gera M, Choudhary K. Dissolution enhancement of drugs. part i: technologies and effect of carriers. Int J Health Res. 2009; 2:107- 124.

2. Pant P, Bansal K, Therdana RPR, Padhee K, Sathapathy A, Kochhar PS, Micronization: an efficient tool for dissolution enhancement of dienogest. Int J Drug Dev Res. 2011; 3:329-333.
3. Dilip V, Pawar AY, Patel JS, Rathi MN, Kothawade PI. Solubility enhancement of aceclofenac by solvent deposition method. Int J Pharm Tech Res. 2010; 2:843-846.
4. Goyal A, Kumar S, Nagpal M, Singh I, Arora S. Potential of novel drug delivery systems for herbal drugs. Ind J Pharm Edu Res. 2011; 45:225- 235.
5. Sandhiya J, Avtar CR, Singh G, Aggarwal G. An overview on solubility enhancement techniques for poorly soluble drugs and solid dispersion as an eminent strategic approach. Int J Pharm Sci Res. 2012; 3:942-956.
6. Mirza AZ, Siddiqui FA. Nanomedicine and drug delivery: a mini review. Int Nano Lett. 2014;4:94.
7. Obeid MA, Al Qaraghuli MM, Alsaadi M, Alzahrani AR, Niwasabutra K, Ferro VA. Delivering natural products and biotherapeutics to improve drug efficacy. Ther Deliv. 2017;8:947–56.
8. Miele E, Spinelli GP, Miele E, Di Fabrizio E, Ferretti E, Tomao S, Gulino A. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomed. 2012;7:3637.
9. McNamara K, Tofail SA. Nanosystems: the use of nanoalloys, metallic, bimetallic, and magnetic nanoparticles in biomedical applications. Phys Chem Chem Phys. 2015;17:27981–95.
10. Saadeh Y, Vyas D. Nanorobotic applications in medicine: current proposals and designs. Am J Robot Surg. 2014;1:4–11.
11. Oliveira ON Jr, Iost RM, Siqueira JR Jr, Crespilho FN, Caseli L. Nanomaterials for diagnosis: challenges and applications in smart devices based on molecular recognition. ACS Appl Mater Interfaces. 2014;6:14745–66.
12. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3:133.
13. Holzinger M, Le Goff A, Cosnier S. Nanomaterials for biosensing applications: a review. Front Chem. 2014;2:63.
14. Golovin YI, Gribanovsky SL, Golovin DY, Klyachko NL, Majouga AG, Master AM, Sokolsky M, Kabanov AV. Towards nanomedicines of the future: remote magneto-mechanical actuation of nanomedicines by alternating magnetic fields. J Control Release. 2015;219:43–60.
15. Lu H, Wang J, Wang T, Zhong J, Bao Y, Hao H. Recent progress on nanostructures for drug delivery applications. J Nanomater. 2016;2016:20.
16. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941.
17. Kumari A, Kumar V, Yadav S. Nanotechnology: a tool to enhance therapeutic values of natural plant products. Trends Med Res. 2012;7:34–42.
18. Shastri, V.P. Non-degradable biocompatible polymers in medicine: Past, present and future. Curr. Pharm. Biotechnol. 2003, 4, 331–337.
19. Almeida, J.P.M.; Chen, A.L.; Foster, A.; Drezek, R.J.N. In vivo biodistribution of nanoparticles. Nanomedicine 2011, 6, 815–835.
20. Chen, H.; Wang, L.; Yeh, J.; Wu, X.; Cao, Z.; Wang, Y.A.; Zhang, M.; Yang, L.; Mao, H. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PMPS copolymer coating. Biomaterials 2010, 31, 5397–5407.
21. Boyer, C.; Whittaker, M.R.; Bulmus, V.; Liu, J.; Davis, T.P. The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications. NPG Asia Mater. 2010, 2, 23–30.
22. Li, P.; Dai, Y.-N.; Zhang, J.-P.; Wang, A.-Q.; Wei, Q. Chitosan-alginate nanoparticles as a novel drug delivery system for nifedipine. Int. J. Biomed. Sci. IJBS 2008, 4, 221–228.
23. Younes, I.; Rinaudo, M. Chitin and chitosan preparation from marine sources. Structure, properties and applications. Mar. Drugs 2015, 13, 1133–1174.
24. De Matteis, L.; Jary, D.; Lucía, A.; García-Embid, S.; Serrano-Sevilla, I.; Pérez, D.; Ainsa, J.A.; Navarro, F.P.; De la Fuente, J.M. New active formulations against M. tuberculosis: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules. Chem. Eng. J. 2018, 340, 181–191.
25. Anversa Dimer, F.; De Souza Carvalho-Wodarz, C.; Goes, A.; Cirnski, K.; Herrmann, J.; Schmitt, V.; Patzold, L.; Abed, N.; De Rossi, C.; Bischo_, M.; et al. PLGA nanocapsules improve the delivery of clarithromycin to kill intracellular Staphylococcus aureus and Mycobacterium abscessus. Nanomedicine 2019, 24, 102125.
26. Jeon, S.J.; Oh, M.; Yeo,W.-S.; Galvao, K.N.; Jeong, K.C. Underlying mechanism of antimicrobial activity of chitosan microparticles and implications for the treatment of infectious diseases. PLoS ONE 2014, 9, e92723.
27. Belbekhouche, S.; Mansour, O.; Carbonnier, B. Promising sub-100 nm tailor made hollow chitosan/poly(acrylic acid) nanocapsules for antibiotic therapy. J. Colloid Interface Sci. 2018, 522, 183–190.
28. Shagholani, H.; Ghoreishi, S.M.; Mousazadeh, M. Improvement of interaction between PVA and chitosan via magnetite nanoparticles for drug delivery application. Int. J. Biol. Macromol. 2015, 78, 130–136.
29. Cafaggi, S.; Russo, E.; Stefani, R.; Leardi, R.; Caviglioli, G.; Parodi, B.; Bignardi, G.; De Totero, D.; Aiello, C.; Viale, M. Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin–alginate complex. J. Control. Release 2007, 121, 110–123.
30. Douglas, K.L.; Tabrizian, M. E_ect of experimental parameters on the formation of alginate–chitosan nanoparticles and evaluation of their potential application as DNA carrier. J. Biomater. Sci. Polym. Ed. 2005, 16, 43–56.

31. Wang, T.; Feng, Z.; He, N.; Wang, Z.; Li, S.; Guo, Y.; Xu, L. A novel preparation of nanocapsules from alginate-oligochitosan. J. Nanosci. Nanotechnol. 2007, 7, 4571–4574.
32. Sarmento, B.; Ferreira, D.; Veiga, F.; Ribeiro, A. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr. Polym. 2006, 66, 1–7.
33. George, M.; Abraham, T.E. Polyionic hydrocolloids for the intestinal delivery of protein drugs: Alginate and chitosan-a review. J. Control. Release 2006, 114, 1–14.
34. Yang, J.; Chen, J.; Pan, D.; Wan, Y.; Wang, Z. pH-sensitive interpenetrating network hydrogels based on chitosan derivatives and alginate for oral drug delivery. Carbohydr. Polym. 2013, 92, 719–725.
35. Mukhopadhyay, P.; Chakraborty, S.; Bhattacharya, S.; Mishra, R.; Kundu, P. pH-sensitive chitosan/alginate core-shell nanoparticles for e_cient and safe oral insulin delivery. Int. J. Biol. Macromol. 2015, 72, 640–648.
36. Dhaneshwar, S.S.; Mini, K.; Gairola, N.; Kadam, S. Dextran: A promising macromolecular drug carrier. Indian J. Pharm. Sci. 2006, 68, 705–714.
37. Tiyaboonchai, W.; Limpeanchob, N. Formulation and characterization of amphotericin B–chitosan–dextran sulfate nanoparticles. Int. J. Pharm. 2007, 329, 142–149.
38. Crecente-Campo, J.; Lorenzo-Abalde, S.; Mora, A.; Marzoa, J.; Csaba, N.; Blanco, J.; Gonzalez-Fernandez, A.; Alonso, M.J. Bilayer polymeric nanocapsules: A formulation approach for a thermostable and adjuvanted E. coli antigen vaccine. J. Control. Release 2018, 286, 20–32.
39. Anitha, A.; Deepagan, V.; Rani, V.D.; Menon, D.; Nair, S.; Jayakumar, R. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate–chitosan nanoparticles. Carbohydr. Polym. 2011, 84, 1158–1164.
40. Tekie, F.S.M.; Kiani, M.; Zakerian, A.; Pilevarian, F.; Assali, A.; Soleimani, M.; Dinarvand, R.; Arefian, E.; Atashi, A.; Amini, M. Nano polyelectrolyte complexes of carboxymethyl dextran and chitosan to improve chitosan-mediated delivery of miR-145. Carbohydr. Polym. 2017, 159, 66–75.
41. Belbekhouche, S.; Oniszczuk, J.; Pawlak, A.; El Joukhar, I.; Go_n, A.; Varrault, G.; Sahali, D.; Carbonnier, B. Cationic poly(cyclodextrin)/alginate nanocapsules: From design to application as e_cient delivery vehicle of 4-hydroxy tamoxifen to podocyte in vitro. Colloids Surf. B Biointerfaces 2019, 179, 128–135.
42. Ismail, M.; Du, Y.; Ling, L.; Li, X. Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria. Int. J. Pharm. 2019, 562, 162–171.
43. Abellan-Pose, R.; Teijeiro-Valino, C.; Santander-Ortega, M.J.; Borrajo, E.; Vidal, A.; Garcia-Fuentes, M.; Csaba, N.; Alonso, M.J. Polyaminoacid nanocapsules for drug delivery to the lymphatic system: E_ect of the particle size. Int. J. Pharm. 2016, 509, 107–117.
44. Mahmoudi, M.; Lynch, I.; Ejtehadi, M.R.; Monopoli, M.P.; Bombelli, F.B.; Laurent, S. Protein□nanoparticle interactions: Opportunities and challenges. Chem. Rev. 2011, 111, 5610–5637.
45. DeFrates, K.; Markiewicz, T.; Gallo, P.; Rack, A.; Weyhmiller, A.; Jarmusik, B.; Hu, X. Protein polymer-based nanoparticles: Fabrication and medical applications. Int. J. Mol. Sci. 2018, 19, 1717.
46. Karimi, M.; Bahrami, S.; Ravari, S.B.; Zangabad, P.S.; Mirshekari, H.; Bozorgomid, M.; Shahreza, S.; Sori, M.; Hamblin, M.R. Albumin nanostructures as advanced drug delivery systems. Expert Opin. Drug Deliv. 2016, 13, 1609–1623.
47. Gaber, M.; Hany, M.; Mokhtar, S.; Helmy, M.W.; Elkodairy, K.A.; Elzoghby, A.O. Boronic-targeted albumin-shell oily-core nanocapsules for synergistic aromatase inhibitor/herbal breast cancer therapy. Mater. Sci. Eng. C 2019, 105, 110099.
48. Toita, R.; Murata, M.; Abe, K.; Narahara, S.; Piao, J.S.; Kang, J.-H.; Ohuchida, K.; Hashizume, M. Biological evaluation of protein nanocapsules containing doxorubicin. Int. J. Nanomed. 2013, 8, 1989–1999.
49. Ren, D.; Kratz, F.; Wang, S.W. Protein nanocapsules containing doxorubicin as a pH-responsive delivery Msystem. Small 2011, 7, 1051–1060.
50. Da Silva Júnior, W.F.; De Oliveira Pinheiro, J.G.; Moreira, C.D.; De Souza, F.J.; De Lima, Á.A. Alternative technologies to improve solubility and stability of poorly water-soluble drugs. In Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics; Elsevier: Amsterdam, The Netherlands, 2017; pp. 281–305.
51. Yao, M.H.; Ma, M.; Chen, Y.; Jia, X.Q.; Xu, G.; Xu, H.X.; Chen, H.R.; Wu, R. Multifunctional Bi2S3/PLGA nanocapsule for combined HIFU/radiation therapy. Biomaterials 2014, 35, 8197–8205.
52. Gomes, M.L.S.; Da Silva Nascimento, N.; Borsato, D.M.; Pretes, A.P.; Nadal, J.M.; Novatski, A.; Gomes, R.Z.; Fernandes, D.; Farago, P.V.; Zanin, S.M.W. Long-lasting anti-platelet activity of cilostazol from poly(epsilon-caprolactone)-poly(ethylene glycol) blend nanocapsules. Mater. Sci. Eng. C 2019, 94, 694–702.
53. Fustier, C.; Chang, T.M. PEG-PLA nanocapsules containing a nanobiotechnological complex of polyhemoglobin-tyrosinase for the depletion of tyrosine in melanoma: Preparation and in vitro characterisation. J. Nanomed. Biother. Discov. 2012, 2, 1–9.
54. Haznedar, S.; Dortunc, B. Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide. Int. J. Pharm. 2004, 269, 131–140.
55. De Gomes, M.G.; Pando Pereira, M.; Guerra Teixeira, F.E.; Carvalho, F.; Pinto Savall, A.S.; Ferreira Bicca, D.; Monteiro Fidelis, E.; Botura, P.E.; Weber Cibin, F.; Pinton, S.; et al. Assessment of unloaded polymeric

nanocapsules with di_erent coatings in female rats: Influence on toxicological and behavioral parameters. Biomed. Pharm. 2020, 121, 109575.
56. Diou, O.; Fattal, E.; Delplace, V.; Mackiewicz, N.; Nicolas, J.; Mériaux, S.; Valette, J.; Robic, C.; Tsapis, N. RGD decoration of PEGylated polyester nanocapsules of perfluorooctyl bromide for tumor imaging: Influence of pre or post-functionalization on capsule morphology. Eur. J. Pharm. Biopharm. 2014, 87, 170–177. Bahmani, B.; Gupta, S.; Vullev, V.I.; Anvari, B.; Upadhyayula, S. E_ect of polyethylene glycol coatings on uptake of indocyanine green loaded nanocapsules by human spleen macrophages in vitro. J. Biomed. Opt. 2011, 16, 051303.
57. De Matteis, L.; Alleva, M.; Serrano-Sevilla, I.; Garcia-Embid, S.; Stepien, G.; Moros, M.; De la Fuente, J.M. Controlling properties and cytotoxicity of chitosan nanocapsules by chemical grafting. Mar. Drugs 2016, 14, 175.
58. Bzowska, M.; Karabasz, A.; Szczepanowicz, K. Encapsulation of camptothecin into pegylated polyelectrolyte nanocarriers. Colloids Surf. A Physicochem. Eng. Asp. 2018, 557, 36–42.
59. Shi, C.; Zhong, S.; Sun, Y.; Xu, L.; He, S.; Dou, Y.; Zhao, S.; Gao, Y.; Cui, X. Sonochemical preparation of folic acid-decorated reductive-responsive epsilon-poly-L-lysine-based microcapsules for targeted drug delivery and reductive-triggered release. Mater. Sci. Eng. C 2020, 106, 110251.
60. Rosa, P.; Friedrich, M.L.; Dos Santos, J.; Librelotto, D.R.N.; Maurer, L.H.; Emanuelli, T.; Da Silva, C.B.; Adams, A.I.H. Desonide nanoencapsulation with acai oil as oil core: Physicochemical characterization, photostability study and in vitro phototoxicity evaluation. J. Photochem. Photobiol. B Biol. 2019, 199, 111606.
61. Venturini, C.G.; Bruinsmann, F.A.; Contri, R.V.; Fonseca, F.N.; Frank, L.A.; D'Amore, C.M.; Ra_n, R.P.; Bu_on, A.; Pohlmann, A.R.; Guterres, S.S. Co-encapsulation of imiquimod and copaiba oil in novel nanostructured systems: Promising formulations against skin carcinoma. Eur. J. Pharm. Sci. 2015, 79, 36–43.
62. Natrajan, D.; Srinivasan, S.; Sundar, K.; Ravindran, A. Formulation of essential oil-loaded chitosan–alginate nanocapsules. J. Food Drug Anal. 2015, 23, 560–568.
63. Abulateefeh, S.R.; Alkawareek, M.Y.; Alkilany, A.M. Tunable sustained release drug delivery system based on mononuclear aqueous core-polymer shell microcapsules. Int. J. Pharm. 2019, 558, 291–298.
64. Cosco, D.; Paolino, D.; De Angelis, F.; Cilurzo, F.; Celia, C.; Di Marzio, L.; Russo, D.; Tsapis, N.; Fattal, E.; Fresta, M. Aqueous-core PEG-coated PLA nanocapsules for an e_cient entrapment of water soluble anticancer drugs and a smart therapeutic response. Eur. J. Pharm. Biopharm. 2015, 89, 30–39.
65. Vrignaud, S.; Anton, N.; Passirani, C.; Benoit, J.P.; Saulnier, P. Aqueous core nanocapsules: A new solution for encapsulating doxorubicin hydrochloride. Drug Dev. Ind. Pharm. 2013, 39, 1706–1711.
66. Lambert, G.; Fattal, E.; Pinto-Alphandary, H.; Gulik, A.; Couvreur, P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides. Int. J. Pharm. 2001, 214, 13–16.
67. Hillaireau, H.; Le Doan, T.; Chacun, H.; Janin, J.; Couvreur, P. Encapsulation of mono-and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers. Int. J. Pharm. 2007, 331, 148–152.
68. Li, S.; He, Y.; Li, C.; Liu, X. In vitro release of protein from poly(butylcyanoacrylate) nanocapsules with an aqueous core. Colloid Polym. Sci. 2004, 283, 480–485.
69. Gil, P.R.; Loretta, L.; Muñoz_Javier, A.; Parak,W.J. Nanoparticle-modified polyelectrolyte capsules. Nano Today 2008, 3, 12–21.
70. Johnston, A.P.; Cortez, C.; Angelatos, A.S.; Caruso, F. Layer-by-layer engineered capsules and their applications. Curr. Opin. Colloid Interface Sci. 2006, 11, 203–209.
71. Shagholani, H.; Ghorbani, M.; Nikpay, A.; Soltani, M. Chitosan nanocapsule-mounted cellulose nanofibrils as nanoships for smart drug delivery systems and treatment of avian trichomoniasis. J. Taiwan Inst. Chem. Eng. 2019, 95, 290–299.
72. Elbaz, N.M.; Owen, A.; Rannard, S.; McDonald, T.O. Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsivemulti-layered nanocapsules for oral drug delivery. Int. J. Pharm. 2019, 574.
73. Menard, M.; Meyer, F.; Parkhomenko, K.; Leuvrey, C.; Francius, G.; Begin-Colin, S.; Mertz, D. Mesoporous silica templated-albumin nanoparticles with high doxorubicin payload for drug delivery assessed with a 3-D tumor cell model. Biochim. Biophys. Acta Gen. Subj. 2019, 1863, 332–341.
74. Shang, B.; Zhang, X.; Ji, R.;Wang, Y.; Hu, H.; Peng, B.; Deng, Z. Preparation of colloidal polydopamine/Au hollow spheres for enhanced ultrasound contrast imaging and photothermal therapy. Mater. Sci. Eng. C 2020, 106, 110174.
75. Rata, D.M.; Cadinoiu, A.N.; Atanase, L.I.; Bacaita, S.E.; Mihalache, C.; Daraba, O.M.; Gherghel, D.; Popa, M. "In vitro" behaviour of aptamer-functionalized polymeric nanocapsules loaded with 5-fluorouracil for targeted therapy. Mater. Sci. Eng. C 2019, 103, 109828.
76. Dubey, V.; Mohan, P.; Dangi, J.S.; Kesavan, K. Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study. Int. J. Biol. Macromol. 2019.
77. Trindade, I.C.; Pound-Lana, G.; Pereira, D.G.S.; De Oliveira, L.A.M.; Andrade, M.S.; Vilela, J.M.C.; Postacchini, B.B.; Mosqueira, V.C.F. Mechanisms of interaction of biodegradable polyester nanocapsules with non-phagocytic cells. Eur. J. Pharm. Sci. 2018, 124, 89–104.
78. Pavan kumar Kothamasu,Hemanth kanumur,Niranjan ravur, Chiranjeevi maddu, Radhika parasuramrajam,

Shivakumar Tangavel. ; Nanocapsule : The weapons for novel drug deliverysystem, 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648923/.

79. Jayanta kumar patra, Gitishree Das, Han-Seung Shin; Nanobased drug delivery system: recent developments and future prospects., 2018. https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-018-0392-8.
80. C. Mayer, department of chemistry, university of Duisburg, essen, Duisburg- Germany. 2005. https://www.researchgate.net/publication/7417147_Nanocapsules_as_Drug_Delivery_Systems.
81. Miss. Manali pisal, Miss. Pranjal Barbade, Prof. Sayali Dudhal. : Nanocapsule ; Internationaljournal of pharmaceutical science,2020.
82. P. R. Radhika*, Shashikanth, T. Shivakumar : Nanocapsule; A new approach in drug delivery.2011.https://ijpsr.com/bft-article/nanocapsules-a-new-approach-in-drug-delivery/
83. P. Karthik, Anandaramakrishnan. C, Narayansinghchahwal :Nano encapsulation techniques for food bioactive components : A Review. 2012. https://link.springer.com/article/10.1007/s11947-012-0944-0
84. Debaleena Das, Nivedita maity, Anuradha H. V. : Nano technology: a revolution in targated drug delivery.;2017. https://www.ijbcp.com/index.php/ijbcp/article/view/2127
85. Jahangirian. H, Lemraski EG, Webster TJ, Rafiee moghaddam R, Abdolkahu Y. : Nanotechnology: a revolution in targeted drug delivery. : 2017. https://www.dovepress.com/a-review-of-drug-delivery- systems-based-on-nanotechnology-and-green-ch-peer-reviewed-fulltext-article-IJN
86. Gouri nilwar, P. B. Mute, P. P. Talhan, Shruti Takre. ; Nanocapsules : nano novel drug deliverysystem; 2017. https://www.pharmatutor.org/articles/nanocapsules-nano-novel-drug- delivery- system?amp
87. Siyuan Deng, Maria Rosa Gigliobianco, Roberta censi and Piera Dimartino. : Polymeric nanocapsule as Nano technological alternative for drug delivery system : Current status,challenges and opportunities. ;2020. https://pubmed.ncbi.nlm.nih.gov/32354008/
88. Dunne M, Corrigan OI and Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials, 21(16), 2000, 1659-68. PubMed
89. Repka M. Hot Melt Extrusion. Encyclopedia of pharmaceutical technology, 2nd ed.; Swarbrick J, Boylan J (Ed.), Marcel Dekker Inc, New York, 2, 2002,PP. 1488-1504.
90. Couvreur P, Barratt G, Fattal E, Legrand P and Vauthier C. Nanocapsule technology- A Review. Crit Rev Ther Drug Carrier Syst, 19(2), 2002, 99-134. PubMed
91. Jang J, Bae J and Park E. Selective fabrication of poly (3, 4- ethylenedioxythiophene) nanocapsules and mesocellular foams using surfactant-mediated interfacial polymerization. Adv Mater, 18(3), 2006 ,354-58.
92. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A and Couvreur .Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm Res, 17(6), 2000,707-14. PubMed
93. Daniel TC, Polina BS and Kimberly AD. Investigating Lyophilization of Lipid Nanocapsules with Fluorescence Correlation Spectroscopy. Langmuir, 26(12), 2010, 10218-22.PMC free article PubMed
94. Aiyer HN, Seshadri R, Raina G, Sen R and Rahul R. Study of Carbon Nanocapsules (Onions) and Spherulitic Graphite by Stm and Other Techniques. In: Fullerene Sci Tech, 3(6),1995, 765-777
95. Watnasirichaikul S, Davies NM, Rades T and Tucker IG. Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharm Res, 17(6), 2000, 684-89. PubMed
96. Sung OC, Eun JL, Hyeok ML, Yue L, Lan YH and Dong PK. Hierarchical pore structures fabricated by electron irradiation of silicone grease and their applications to superhydrophobic and superhydrophilic films. Macromol Rapid Commun, 28(3), 2007, 246-51.
97. Douglas AW and Zeno WW. Blocked isocyanates III: Part A. Mechanisms and chemistry. Progress in Organic Coatings, 36(3),1999, 148-72.
98. Kepczynski M, Bednar J, Lewandowska J, Staszewska M and NowakowskaM . Hybrid silicasiliconenanocapsules obtained in catanionicvesicles .Cryo-TEM studies. J NanosciNanotechnol, 9(5), 2009,3138-43. PubMed
99. Song Ma, Dianyu G, Weishan Z, Wei L, Xiuliang M and Zhidong Z. Synthesis of a new type of GdAl2 nanocapsule with a large cryogenic magnetocaloric effect and novel coral-like aggregates self-assembled by nanocapsules. Nanotechnology, 17(21), 2006,5406-11.
100. Pohlmann R, Beck RCR, Lionzo MIZ, Coasta TMH, Benvenutti EV, Re MI, et al. Surface morphology of spray-dried nanoparticle-coated microparticles designed as an oral drug delivery system. Braz J ChemEng, 25(2), 2008,389-98.
101. Liu XG, Li B, Geng DY, Cui WB, Yang F, Xie ZG, et al. (Fe, Ni)/C nanocapsules for electromagnetic-wave-absorber in the whole Ku-band. Carbon, 47(2), 2009,470-74.
102. Kedersha NL. Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry. J Cell Biol, 112(2), 1991 ,225- 35. PMC free article PubMed
103. Leonard HR, Hal M, Bruce D, Jeffrey Z and James H. The Development of Vault Nano Capsules. NSF Nanoscale Science and Engineering Grantees Conference, 2003,1-3.
104. Sangwoo P, Hong YC, Jeong YA, Yungwan K, Abiraman S, Jeffrey O, et al. Photo-Cross-Linkable Thermoresponsive Star Polymers Designed for Control

of Cell- Surface Interactions. Biomacromolecules, 11(10), 2010,2647-52. PubMed

105. Bouchemal K, Briançon S, Perrier E, Fessi H, Bonnet I and Zydowicz N. Synthesis and characterization of polyurethane and poly (ether urethane) nanocapsules using a new technique of interfacial polycondensation combined to spontaneous emulsification. Int J Pharm, 269(1), 2004,89-100. PubMed
106. Hildebrand GE and Tack JW. 2000. Microencapsulation of peptides and proteins. *Int J Pharm*, 196(2), 173–76.
107. Damge C, Michel C, Aprahamian M, Couvreur P and Devissaguet JP. 1990. Nanocapsules as carriers for oral peptide delivery. *J Control Release*, 13(2-3), 233-239.
108. Jack MR, Celine B, Laurence M, Herv H, Vronique M, Elisabeth C, *et al.* 2008. Physicochemical characteristics andpreliminary *in vivo* biological evaluation of nanocapsules loaded with siRNA targeting estrogen receptor alpha. *Biomacromolecules*, 9(10), 2881–90.
109. Panagiotis V, Matthieu F, Antoine F and Constantinos M. 2011. MRI-Guided Nanorobotic Systems for Therapeutic and Diagnostic Applications. *Annu Rev Biomed Eng*, 13(1), 157-84.
110. Betsy TK, Gretchen MU, Mark TR and Clifford JS. 2006. Targeted Nanocapsules for Liver Cell-Type Delivery of Plasmids *in vivo. Mol Ther*, 13, S415.
111. Deutsch E, Libson K, Vanderheyden JL, Ketring AR and Maxon HR. 1986. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. *Int J Rad Appl Instrum B*, 13(4), 465–77.
112. Dong XT, Zhang L, Zhang W, Wang LP and Hong GY. 2001. Preparation and Characterization of Nanometer-sized CeO2 /Polystyrene Hybrid Material. *Acta Phys Chim Sin*, 17(8), 739-42.
113. Hwang SL and Kim JC. 2008. *In vivo* hair growth promotion effects of cosmetic preparations containing hinokitiol-loaded poly (ε-caprolacton) nanocapsules. *J Microencapsul.* 25(5), 351-56.
114. Sao K, Murata M, Umezaki K, Fujisaki Y, Mori T, Niidome T, *et al*. 2009. Molecular design of protein-based nanocapsules for stimulus-responsive characteristics. *Bioorg Med Che*, 17(1), 85-93.
115. Marie Curie. 2011. Novel lipid nanocapsules of anti alpha 1 sodium pump subunit SiRNA to specifically target metastatic melanomas. *European commission euraxess*, 11, 37.
116. Falqueiro M, Primo FL, Morais PC, Mosiniewicz S, Suchocki P and Tedesco AC. 2011. Selol-loaded magnetic nanocapsules: A new approach for hyperthermia cancer therapy. *J Appl Phys*, 109, 07B306.
117. Michael Berger. 2009. Integrating nanotube-based NEMS into large scale MEMS. *Nanowerk LLC*, 5, 316-22. Available on: http://www.nanowerk.com/spotlight/spotid=11804.php
118. Radhika PR, Sasikanth and Sivakumar T. 2011. Nanocapsules: A new approach for drug delivery. *Int J Pharma Sci Res*, 2(6), 1426-29.